Searching for a cure, Improving lives

Sarepta recruits for Phase 3 ESSENCE trial to test two potential therapies

Posted on: June 19th, 2017 | 0 comments

Sarepta Therapeutics is recruiting up to 99 boys with Duchenne muscular dystrophy to test two new compounds, SRP-4045 and SRP-4053, in a Phase 3 clinical trial.

The ESSENCE study is a double-blind, placebo-controlled, multi-center Phase 3 clinical trial (NCT02500381) with an open-label extension period, evaluating the two drugs’ safety and efficacy in boys between 7 to 13 years of age, with a confirmed deletion amenable to exon 45 or 53 skipping.

Sarepta plans to target at least 45 boys potentially responsive or amenable to exon 45 skipping with SRP-4045, and 45 boys potentially responsive or amenable to exon 53 skipping with SRP-4053. The boys will be randomised to receive once-a-week intravenous infusions of 30 mg/kg SRP-4045 or 30 mg/kg SRP-4053 or placebo, for up to 96 weeks. Then, in the open-label extension phase, all boys will receive open-label active treatment for up to 96 weeks.

After about 75 of the boys have been in the trial for 48 weeks, researchers will review the initial results to determine which patients are eligible to enroll in the open-label extension period.

The study’s primary objective is to test the efficacy of both compounds, which will be assessed at regular study visits, with functional tests such as the six-minute walk test (6MWT). All patients will undergo a muscle biopsy at baseline and a second muscle biopsy at week 48. Sarepta will assess the drugs’ safety through adverse events, laboratory tests, electrocardiograms, echocardiograms, vital signs, and physical examinations. In addition, to assess how both drugs work in the body, researchers will collect blood samples from patients throughout the study.

SRP-4045 and SRP-4053 are designed to address the underlying cause of Duchenne by enabling the production of a shorter, but functional, form of the dystrophin protein. Neither the U.S. Food and Drug Administration nor any other regulatory agency has approved these drugs to treat Duchenne.

Sarepta, based in Cambridge, Massachusetts, is conducting the trial at 17 study sites across the United States, as well as sites in Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden and the United Kingdom. More information about how to enrol in this study can be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Action Duchenne launches new Research Strategy for Duchenne muscular dystrophy

November 17th, 2017

  Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is

Tell me more

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

FDA new approach would reduce number of patients treated with placebo

December 11th, 2017

The U.S. Food and Drug Administration (FDA) has published its recommendation for a new approach

Tell me more

Results announced from survey ‘Juggling care and daily life’

December 11th, 2017

The 17th October 2017 was an important date for the rare disease community.  The highlights of the

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne